Iloprost in Preventing Lung Cancer in Former Smokers

Status Completed

Clinical Trial Summary

This phase I trial studies the side effects and best dose of iloprost compared with a placebo in preventing lung cancer in former smokers. Chemoprevention is the use of drugs to keep cancer from forming or coming back. Inhaled iloprost may help prevent lung cancer from forming in patients who used to smoke and who have been found to have abnormal cells in their mucus.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To evaluate the toxicity of inhalational iloprost administered to patients daily for 2 months, given four times a day (QID). SECONDARY OBJECTIVES: I. To evaluate the compliance QID dosing regimens. II. To evaluate the effect on endobronchial histology. III. To evaluate the effect on expectorated sputum cytology by both standard cytologic analysis and an automated three-dimensional morphologic analysis. IV. To evaluate the effect on endobronchial brushing and biopsy gene expression of peroxisome proliferator-activated receptor gamma (PPARgamma), glutathione S-transferase mu (GSTmu), carboxylesterase 1 (Ces1), Fos-related antigen 1 (FosL1), cytochrome p4502e1, stearoyl coA desaturase 1, tumor necrosis factor (TNF) superfamily member 9, transforming growth factor beta (TGFbeta), Jun and a 46 gene panel associated with dysplasia persistence, using Affymetrix arrays. V. To evaluate the improvement in chronic obstructive pulmonary disease (COPD) as measured by arterial blood gas (ABG) (improved ventilation perfusion matching), pulmonary function testing, 6-minute walk distance, quality of life (St. George's respiratory questionnaire, COPD assessment test [CAT]). VI. To evaluate whether the in vitro response of cultured airway epithelial progenitor cells to iloprost is a predictor of in vivo response in study subjects. OUTLINE: Patients are enrolled to Cohort A to completion prior to initiation of Cohort B. COHORT A: Patients are assigned to 1 of 2 arms. ARM I: Patients receive iloprost via inhalation using a nebulizer QID for 60 days. ARM II: Patients receive placebo via inhalation using a nebulizer QID for 60 days. COHORT B: Patients are assigned to 1 of 2 arms. COHORT B DISCONTINUED AS OF 03/26/2019. ARM III: Patients receive iloprost via inhalation using a nebulizer BID for 60 days. ARM IV: Patients receive placebo via inhalation using a nebulizer BID for 60 days. After completion of study treatment, patients are followed up at 90 days and then annually for up to 5 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02237183
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 1
Start date	November 5, 2015
Completion date	August 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04931017` - Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer	Phase 2
Recruiting	`NCT05898594` - Lung Cancer Screening in High-risk Black Women	N/A
Not yet recruiting	`NCT06038526` - Evaluation of Canakinumab in High-Risk Former-Smokers	Phase 2
Terminated	`NCT02856581` - Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes	Phase 3
Completed	`NCT04922697` - Educational Intervention for the Promotion of Knowledge and Preventive Health Behaviors Related to Personal Air Pollution Exposure, The Air Study	N/A
Recruiting	`NCT04644952` - The Rise in Robotic Atypical Segmentectomies
Completed	`NCT01896778` - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer	N/A
Recruiting	`NCT05407168` - Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool	N/A
Completed	`NCT04267874` - Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study	Early Phase 1
Recruiting	`NCT02408861` - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Phase 1
Recruiting	`NCT03709953` - Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma	Phase 2
Active, not recruiting	`NCT03267524` - Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers	N/A
Recruiting	`NCT04147494` - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues	Early Phase 1
Recruiting	`NCT04783168` - Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study	N/A
Completed	`NCT04635761` - Awareness, Information, and Resources for Lung Cancer Screening Program for Community-Partnered Lung Cancer Screening	N/A
Active, not recruiting	`NCT03164486` - First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide	Early Phase 1
Recruiting	`NCT05802186` - Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study	N/A
Active, not recruiting	`NCT01696968` - Screening for Lung Cancer in Older Patients (PLCO Screening Trial)	N/A
Recruiting	`NCT04410302` - Patient-Derived Xenografts to Reduce Cancer Health Disparities
Recruiting	`NCT04969341` - Improving Lung Cancer Screening Adherence by Overcoming Barriers for Vulnerable Populations